p. 1−1
1110-0400
Vol.46/No.2
p. 315−322
1110-0400
Vol.46/No.2
p. 323−330
1110-0400
Vol.46/No.2
p. 331−344
1110-0400
Vol.46/No.2
p. 345−350
1110-0400
Vol.46/No.2
p. 351−362
1110-0400
Vol.46/No.2
p. 363−372
1110-0400
Vol.46/No.2
p. 373−382
1110-0400
Vol.46/No.2
p. 383−390
1110-0400
Vol.46/No.2
p. 391−404
1110-0400
Vol.46/No.2
p. 405−412
1110-0400
Vol.46/No.2
p. 413−424
1110-0400
Vol.46/No.2
p. 425−432
1110-0400
Vol.46/No.2
p. 433−442
1110-0400
Vol.46/No.2
51.5 Pg/ml, IgE >60IU/ml and the number of eosinophils >2.8% in the mild form of asthma, while the cutoff values for IL17>92.9Pg/ml, IgE>162.0IU/ml and the number of eosinophils >4.1%) in the severer form of asthma. Sensitivity, specificity and positive predictive value for IgE level in mild asthma were 85%, 80% and 77.8% respectively, while in severe asthma 65%, 85% and 83% respectively. Moreover, sensitivity, specificity, positive predictive values for IL17 in mild asthma were 97.5%, 100% and 100% respectively, while in severe asthma were 100%, 100% and 100% respectively.
Conclusion: Simple spirometric parameters (bedside test) were a good predictive tool for assessment asthma severity. Among laboratory tests, IL17 was the best biomarker for diagnosis and prediction of asthma severity in asthmatic patients than IgE.]]>
p. 443−454
1110-0400
Vol.46/No.2
p. 455−462
1110-0400
Vol.46/No.2
p. 463−478
1110-0400
Vol.46/No.2
p. 479−486
1110-0400
Vol.46/No.2
p. 487−494
1110-0400
Vol.46/No.2
p. 495−506
1110-0400
Vol.46/No.2
p. 507−514
1110-0400
Vol.46/No.2
p. 515−530
1110-0400
Vol.46/No.2
p. 531−540
1110-0400
Vol.46/No.2
p. 541−556
1110-0400
Vol.46/No.2
p. 557−569
1110-0400
Vol.46/No.2